ArticlePLoS genetics2013
Gene set signature of reversal reaction type I in leprosy patients.
Article in PLoS genetics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Pleiotropic effects for Parkin and LRRK2 in leprosy type-1 reactions and Parkinson's disease.Proceedings of the National Academy of Sciences of the United States of America · 2019Trial
- AZALEP a randomized controlled trial of azathioprine to treat leprosy nerve damage and Type 1 reactions in India: Main findings.PLoS neglected tropical diseases · 2017Trial
- Leprosy.Nature reviews. Disease primers · 2024Review
- Review
- Article
- Transcription factor MAFB controls type I and II interferon response-mediated host immunity inFrontiers in microbiology · 2022Article
- Blood RNA signature RISK4LEP predicts leprosy years before clinical onset.EBioMedicine · 2021Article
- Transcriptomic Analysis ofFrontiers in cellular and infection microbiology · 2021Article
- Host-Related Laboratory Parameters for Leprosy Reactions.Frontiers in medicine · 2021Review
- Advances in the Immunology and Genetics of Leprosy.Frontiers in immunology · 2020Review
- Whole blood RNA signatures in leprosy patients identify reversal reactions before clinical onset: a prospective, multicenter study.Scientific reports · 2019Article
- Identification of a systemic interferon-γ inducible antimicrobial gene signature in leprosy patients undergoing reversal reaction.PLoS neglected tropical diseases · 2019Article
- Whole blood profiling of leprosy type 1(reversal) reactions highlights prominence of innate immune response genes.BMC infectious diseases · 2018Article
- Human genetics of mycobacterial disease.Mammalian genome : official journal of the International Mammalian Genome Society · 2018Review
- Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives.The Lancet. Infectious diseases · 2018Review
- Host Lipid Mediators in Leprosy: The Hypothesized Contributions to Pathogenesis.Frontiers in immunology · 2018Review
- Deciphering the genetic control of gene expression following Mycobacterium leprae antigen stimulation.PLoS genetics · 2017Article
- A genome wide association study identifies a lncRna as risk factor for pathological inflammatory responses in leprosy.PLoS genetics · 2017Article
- Age-Dependent Association ofFrontiers in immunology · 2017Article
- A Missense LRRK2 Variant Is a Risk Factor for Excessive Inflammatory Responses in Leprosy.PLoS neglected tropical diseases · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Leprosy reversal reactions type 1 (T1R) are acute immune episodes that affect a subset of leprosy patients and remain a major cause of nerve damage. Little is known about the relative importance of innate versus environmental factors in the pathogenesis of T1R. In a retrospective design, we evaluated innate differences in response to Mycobacterium leprae between healthy individuals and former leprosy patients affected or free of T1R by analyzing the transcriptome response of whole blood to M. leprae sonicate. Validation of results was conducted in a subsequent prospective study. We observed the differential expression of 581 genes upon exposure of whole blood to M. leprae sonicate in the retrospective study. We defined a 44 T1R gene set signature of differentially regulated genes. The majority of the T1R set genes were represented by three functional groups: i) pro-inflammatory regulators; ii) arachidonic acid metabolism mediators; and iii) regulators of anti-inflammation. The validity of the T1R gene set signature was replicated in the prospective arm of the study. The T1R genetic signature encompasses genes encoding pro- and anti-inflammatory mediators of innate immunity. This suggests an innate defect in the regulation of the inflammatory response to M. leprae antigens. The identified T1R gene set represents a critical first step towards a genetic profile of leprosy patients who are at increased risk of T1R and concomitant nerve damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.